fingolimod hydrochloride has been researched along with Arachnoidal Cerebellar Sarcoma, Circumscribed in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Brunetto, AL; Brunetto, AT; da Cunha Jaeger, M; da Silveira Perla, A; Dalmolin, MGS; de Farias, CB; Fratini, L; Roesler, R; Sinigaglia, M | 1 |
| Cardoso, PS; da Cunha Jaeger, M; de Farias, CB; Fratini, L; Perla, AS; Roesler, R | 1 |
| Aye, JM; Beierle, EA; Friedman, GK; Garner, EF; Moore, BP; Mroczek-Musulman, E; Stafman, LL; Stewart, JE; Williams, AP | 1 |
3 other study(ies) available for fingolimod hydrochloride and Arachnoidal Cerebellar Sarcoma, Circumscribed
| Article | Year |
|---|---|
ZEB1 is a Subgroup-Specific Marker of Prognosis and Potential Drug Target in Medulloblastoma.
Topics: Adolescent; Brain Neoplasms; Cerebellar Neoplasms; Cerebellum; Child; Fingolimod Hydrochloride; Histone Deacetylase Inhibitors; Humans; Medulloblastoma; Zinc Finger E-box-Binding Homeobox 1 | 2023 |
Fingolimod (FTY720) reduces viability and survival and increases histone H3 acetylation in medulloblastoma cells.
Topics: Acetylation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Medulloblastoma | 2020 |
FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Disease Models, Animal; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Medulloblastoma; Mice; Xenograft Model Antitumor Assays | 2018 |